SG11201906386XA - Combination therapy involving diaryl macrocyclic compounds - Google Patents
Combination therapy involving diaryl macrocyclic compoundsInfo
- Publication number
- SG11201906386XA SG11201906386XA SG11201906386XA SG11201906386XA SG11201906386XA SG 11201906386X A SG11201906386X A SG 11201906386XA SG 11201906386X A SG11201906386X A SG 11201906386XA SG 11201906386X A SG11201906386X A SG 11201906386XA SG 11201906386X A SG11201906386X A SG 11201906386XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- ste
- january
- pct
- Prior art date
Links
- -1 diaryl macrocyclic compounds Chemical class 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012830 cancer therapeutic Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940121647 egfr inhibitor Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762450455P | 2017-01-25 | 2017-01-25 | |
| US201862619165P | 2018-01-19 | 2018-01-19 | |
| PCT/US2018/015150 WO2018140554A1 (en) | 2017-01-25 | 2018-01-25 | Combination therapy involving diaryl macrocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906386XA true SG11201906386XA (en) | 2019-08-27 |
Family
ID=62979021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906386XA SG11201906386XA (en) | 2017-01-25 | 2018-01-25 | Combination therapy involving diaryl macrocyclic compounds |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11291667B2 (enExample) |
| EP (1) | EP3573991A4 (enExample) |
| JP (1) | JP7193475B2 (enExample) |
| KR (1) | KR102618773B1 (enExample) |
| CN (1) | CN110291092A (enExample) |
| AU (1) | AU2018212647B2 (enExample) |
| BR (1) | BR112019015115A2 (enExample) |
| CA (1) | CA3049548A1 (enExample) |
| IL (1) | IL267992B2 (enExample) |
| MX (1) | MX2019008701A (enExample) |
| SG (1) | SG11201906386XA (enExample) |
| TW (1) | TWI808958B (enExample) |
| WO (1) | WO2018140554A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015112806A2 (en) | 2014-01-24 | 2015-07-30 | Tp Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| ES2864839T3 (es) | 2015-07-02 | 2021-10-14 | Turning Point Therapeutics Inc | Macrociclos de diarilo quirales como moduladores de proteína quinasas |
| MX383823B (es) | 2015-07-21 | 2025-03-14 | Turning Point Therapeutics Inc | Macrociclos de diarilo quirales y usos de los mismo. |
| CN109715165A (zh) | 2016-07-28 | 2019-05-03 | Tp生物医药公司 | 巨环激酶抑制剂 |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| MY201925A (en) | 2017-07-28 | 2024-03-23 | Turning Point Therapeutics Inc | Macrocyclic compounds and uses thereof |
| JP7194188B2 (ja) | 2017-12-19 | 2022-12-21 | ターニング・ポイント・セラピューティクス・インコーポレイテッド | 疾患を治療するための大環状化合物 |
| KR102850357B1 (ko) | 2018-10-22 | 2025-08-27 | 알루미스 인크. | Tyk2 억제제 및 이의 용도 |
| CN111171049B (zh) * | 2018-11-09 | 2021-06-04 | 山东轩竹医药科技有限公司 | 酪氨酸激酶抑制剂及其用途 |
| TW202133855A (zh) * | 2019-11-27 | 2021-09-16 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| CA3163095A1 (en) * | 2019-11-27 | 2021-06-03 | Turning Point Therapeutics, Inc. | Combination therapy involving diaryl macrocyclic compounds |
| CN113121568A (zh) * | 2019-12-31 | 2021-07-16 | 成都倍特药业股份有限公司 | 一种大环结构化合物的盐及其制备方法 |
| US20230219978A1 (en) * | 2020-06-04 | 2023-07-13 | Scinnohub Pharmaceutical Co., Ltd | Compound having macrocyclic structure and use thereof |
| AU2021345181A1 (en) * | 2020-09-16 | 2023-05-04 | Alumis Inc | Tyk2 inhibitors and uses thereof |
| CN114057771B (zh) * | 2020-12-03 | 2023-10-03 | 北京鞍石生物科技有限责任公司 | 大环化合物及其制备方法和应用 |
| CN116063326B (zh) * | 2021-11-02 | 2025-08-05 | 赛诺哈勃药业（成都）有限公司 | 作为蛋白激酶调节剂的含氨基大环化合物 |
| IL313670A (en) | 2021-12-30 | 2024-08-01 | Biomea Fusion Inc | Pyrazine compounds as inhibitors of FLT3 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994021608A1 (en) | 1993-03-25 | 1994-09-29 | The Upjohn Company | Indoletetralins having dopaminergic activity |
| AU687909B2 (en) | 1993-12-07 | 1998-03-05 | Eli Lilly And Company | Protein kinase C inhibitors |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6251912B1 (en) | 1997-08-01 | 2001-06-26 | American Cyanamid Company | Substituted quinazoline derivatives |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| CN1138778C (zh) | 1998-05-26 | 2004-02-18 | 沃尼尔·朗伯公司 | 用作细胞增殖抑制剂的二环嘧啶及二环3,4-二氢嘧啶化合物及用途 |
| ATE301661T1 (de) | 2000-12-08 | 2005-08-15 | Ortho Mcneil Pharm Inc | Makroheterocyclische verbindungen als kinase inhibitoren |
| US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| DE10063435A1 (de) | 2000-12-20 | 2002-07-04 | Boehringer Ingelheim Pharma | Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE10307165A1 (de) | 2003-02-20 | 2004-09-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung |
| DE10349113A1 (de) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
| TWI377944B (en) | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| JP5749645B2 (ja) | 2008-09-08 | 2015-07-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | タンパク質キナーゼ阻害剤としての大環状ピリミジン |
| EP2350075B1 (en) | 2008-09-22 | 2014-03-05 | Array Biopharma, Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
| KR101853026B1 (ko) | 2008-10-22 | 2018-04-27 | 어레이 바이오파마 인크. | ＴＲＫ 키나아제 억제제로서 치환된 피라졸로［１,５ａ］ 피리미딘 화합물 |
| EP2348860B1 (en) | 2008-10-31 | 2015-05-27 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
| ES2446720T3 (es) | 2009-10-13 | 2014-03-10 | Elanco Animal Health Ireland Limited | Inhibidores de la integrasa macrocíclica |
| WO2011071491A1 (en) | 2009-12-09 | 2011-06-16 | Signal Pharmaceuticals, Llc | Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol |
| SA111320200B1 (ar) * | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| CN105693720B (zh) | 2010-05-20 | 2019-01-18 | 阵列生物制药公司 | 作为trk激酶抑制剂的大环化合物 |
| KR101217526B1 (ko) | 2010-06-11 | 2013-01-02 | 한미사이언스 주식회사 | 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| US8828391B2 (en) * | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| WO2013001310A1 (en) | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| EP2744507A4 (en) | 2011-08-19 | 2015-01-28 | Merck Sharp & Dohme | CRYSTAL FORMS OF AN HCV PROTEASE HEMMER |
| US9090630B2 (en) | 2011-09-30 | 2015-07-28 | Oncodesign S.A. | Macrocyclic FLT3 kinase inhibitors |
| ES2621220T3 (es) | 2012-03-06 | 2017-07-03 | Pfizer Inc. | Derivados macrocíclicos para el tratamiento de enfermedades proliferativas |
| MX381849B (es) | 2012-03-09 | 2025-03-13 | Lexicon Pharmaceuticals Inc | Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso. |
| EP2822559B1 (en) | 2012-03-09 | 2018-05-02 | Lexicon Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and uses thereof |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| BR112015023020A2 (pt) * | 2013-03-14 | 2017-07-18 | Pfizer | combinação de inibidor de egfr t790m e inibidor de egfr para o tratamento de câncer pulmonar de células não-pequenas |
| TW201601753A (zh) * | 2013-09-30 | 2016-01-16 | 第一三共股份有限公司 | 蛋白質生物標記及其用途 |
| WO2015112806A2 (en) * | 2014-01-24 | 2015-07-30 | Tp Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| ES2864839T3 (es) | 2015-07-02 | 2021-10-14 | Turning Point Therapeutics Inc | Macrociclos de diarilo quirales como moduladores de proteína quinasas |
| ES2979111T3 (es) * | 2015-07-06 | 2024-09-24 | Turning Point Therapeutics Inc | Polimorfo de macrociclo de diarilo |
| MX383823B (es) | 2015-07-21 | 2025-03-14 | Turning Point Therapeutics Inc | Macrociclos de diarilo quirales y usos de los mismo. |
| US9890163B2 (en) * | 2015-10-15 | 2018-02-13 | Princeton Drug Discovery Inc | Inhibitors of protein kinases |
| CN109715165A (zh) | 2016-07-28 | 2019-05-03 | Tp生物医药公司 | 巨环激酶抑制剂 |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| MY201925A (en) | 2017-07-28 | 2024-03-23 | Turning Point Therapeutics Inc | Macrocyclic compounds and uses thereof |
| WO2019120267A1 (zh) | 2017-12-22 | 2019-06-27 | 成都先导药物开发股份有限公司 | 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂 |
| AU2019254979B2 (en) | 2018-04-18 | 2021-08-12 | Hitgen Inc. | Macrocyclic kinase inhibitor |
-
2018
- 2018-01-24 TW TW107102558A patent/TWI808958B/zh active
- 2018-01-25 CN CN201880008596.6A patent/CN110291092A/zh active Pending
- 2018-01-25 AU AU2018212647A patent/AU2018212647B2/en active Active
- 2018-01-25 US US16/480,557 patent/US11291667B2/en active Active
- 2018-01-25 CA CA3049548A patent/CA3049548A1/en active Pending
- 2018-01-25 KR KR1020197021227A patent/KR102618773B1/ko active Active
- 2018-01-25 SG SG11201906386XA patent/SG11201906386XA/en unknown
- 2018-01-25 BR BR112019015115-0A patent/BR112019015115A2/pt not_active Application Discontinuation
- 2018-01-25 JP JP2019560071A patent/JP7193475B2/ja active Active
- 2018-01-25 EP EP18745012.7A patent/EP3573991A4/en not_active Withdrawn
- 2018-01-25 MX MX2019008701A patent/MX2019008701A/es unknown
- 2018-01-25 WO PCT/US2018/015150 patent/WO2018140554A1/en not_active Ceased
-
2019
- 2019-07-11 IL IL267992A patent/IL267992B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019126642A (ru) | 2021-02-26 |
| BR112019015115A2 (pt) | 2020-03-10 |
| IL267992A (en) | 2019-09-26 |
| IL267992B (en) | 2022-10-01 |
| EP3573991A1 (en) | 2019-12-04 |
| IL267992B2 (en) | 2023-02-01 |
| CA3049548A1 (en) | 2018-08-02 |
| JP7193475B2 (ja) | 2022-12-20 |
| KR102618773B1 (ko) | 2023-12-27 |
| CN110291092A (zh) | 2019-09-27 |
| WO2018140554A1 (en) | 2018-08-02 |
| RU2019126642A3 (enExample) | 2021-03-31 |
| MX2019008701A (es) | 2019-09-13 |
| EP3573991A4 (en) | 2021-01-20 |
| US11291667B2 (en) | 2022-04-05 |
| TW201831188A (zh) | 2018-09-01 |
| US20190381048A1 (en) | 2019-12-19 |
| JP2020514409A (ja) | 2020-05-21 |
| AU2018212647A1 (en) | 2019-07-11 |
| KR20190111939A (ko) | 2019-10-02 |
| AU2018212647B2 (en) | 2022-02-03 |
| TWI808958B (zh) | 2023-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201907056XA (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201901390TA (en) | Tetracycline compounds and methods of treatment | |
| SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201900883UA (en) | Combination treatment for hematological cancers | |
| SG11201810872UA (en) | Composition and method for reducing neutropenia | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201901228QA (en) | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide | |
| SG11201805001UA (en) | Method of treating influenza a |